ASH 2024: Focus on CAR-T

Review key research and clinical insights on CAR-T cell therapy presented at the 66th ASH Annual Meeting and Exposition.

Exploring CAR-T in the Second- Versus Third-Line or Later Setting in LBCL

CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.

Promising Initial Data for Investigational Anti-CD19 CAR T-Cell Therapy in Autoimmune Diseases

The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.

$Five Years In, Axi-Cel Proves Resilience as Relapsed and Refractory iNHL Treatment$

Five Years In, Axi-Cel Proves Resilience as Relapsed and Refractory iNHL Treatment

The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.

CAR22 Delivers Breakthrough Results in Small MCL/FL Cohort

The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.

Better CAR T-Cell Outcomes Shown in Transformed Follicular Lymphoma Versus DLBCL

Dr. Matthew Cortese reported that CAR T-cell therapy appears to overcome some of the adverse prognostic impact.

Early Results Highlight Promise of Autologous CAR T-Cell Combination Therapy

The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.

Data Support Front-Line Rituximab in Advanced, Low-Tumor Burden Follicular Lymphoma

Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.

$Liso-Cel Response Rate Near 100% in Patients With Relapsed or Refractory Follicular Lymphoma$

Liso-Cel Response Rate Near 100% in Patients With Relapsed or Refractory Follicular Lymphoma

According to Jeremey S. Abramson, MD, TRANSCEND FL showed the highest CR ever reported in high-risk follicular lymphoma.

$WZTL-002 CAR T Cells Show Potential in Treatment of Relapsed or Refractory B-Cell NHL$

WZTL-002 CAR T Cells Show Potential in Treatment of Relapsed or Refractory B-Cell NHL

Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.

$CTX112 Yields Clinically Meaningful Results in Relapsed or Refractory B-Cell Malignancies$

CTX112 Yields Clinically Meaningful Results in Relapsed or Refractory B-Cell Malignancies

CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.

First-in-Human Phase I Study Results Presented: Trispecific CAR T-Cell Therapy

The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.

Beta-Hydroxybutyrate Content in Diet: A Potential Avenue for CAR T-Cell Efficacy Enhancement

Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.

Liso-Cel Sustains Clinical Benefit Over Two Years in R/R CLL, SLL

Results from the TRANSCEND CLL 004 show continued benefit of lisocabtagene maraleucel for R/R CLL treatment.

Standard Of Care CD19 CAR T-Cell Therapy in Transformed Indolent Lymphoma Evaluated

A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.

OLYMPIA-1 Trial: Odronextamab Demonstrates 100% ORR, CR Rate in High-Risk Follicular Lymphoma

Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma.

Long-Term Outcomes of Tisagenlecleucel in Follicular Lymphoma

Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.

Inhibition of Caspase-1 Improves CAR T-Cell Safety, Efficacy

Favorable preclinical outcomes were demonstrated with VX765 treatment.

Firicabtagene Autoleucel Potentially Curative for CAR19-Progressing LBCL

Phase 1 study results hint response durability for novel CAR-T agent, CAR22 in certain patients with large B-cell lymphoma.

What Is the Link Between Tumor Features, CAR-T Response in MCL?

Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response.

TRANSCEND CLL Trial: Liso-cel Plus Ibrutinib Provides ‘Promising New Therapeutic Strategy’

Liso-cel plus ibrutinib demonstrates substantial efficacy, deep remissions, and manageable safety.

Liso-cel Versus Mosunetuzumab in Follicular Lymphoma: Cost, Clinical Outcomes, Time Toxicity

Although liso-cel has a higher total cost than mosunetuzumab, it provides increased survival and reduced time toxicity.

Anti-CD19 CAR T-Cell Therapy Shows ‘Clinically Significant’ Response Rates in Richter’s Transformation

Patients treated with tisa-cel, axi-cel, or liso-cel had an ORR of 65% and a one-month CR rate of 46%.